{"abstract":"The National Institute on Aging, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the U.S. and International Patents and Patent Applications listed in the Supplementary Information section of this notice to CTS Biopharma LLC, located in Sunnyvale, CA.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2018/03/16/2018-05310.html","cfr_references":[],"citation":"83 FR 11762","comment_url":null,"comments_close_on":"2018-04-02","correction_of":null,"corrections":[],"dates":"Only written comments and/or complete applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before April 2, 2018 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2018-05310","effective_on":null,"end_page":11763,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2018/03/16/2018-05310.xml","html_url":"https://www.federalregister.gov/documents/2018/03/16/2018-05310/prospective-grant-of-an-exclusive-patent-license-anti-marinobufagenin-antibodies-and-methods-for","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2018-05310?publication_date=2018-03-16","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2018-03-16/2018-05310/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":175,"last_updated":"2026-10-23 12:15:06 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2018-03-16/pdf/2018-05310.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2018-05310.pdf?1521117917","publication_date":"2018-03-16","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2018/03/16/2018-05310.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-02-28T20:02:04Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":11762,"subtype":null,"title":"Prospective Grant of an Exclusive Patent License: Anti-Marinobufagenin Antibodies and Methods for Diagnosis and Treatment of Cardiovascular Disease and Fibrotic Disease","toc_doc":"Anti-Marinobufagenin Antibodies and Methods for Diagnosis and Treatment of Cardiovascular Disease and Fibrotic Disease","toc_subject":"Prospective Grants of Exclusive Patent Licenses:","topics":[],"type":"Notice","volume":83}